TABLE 2.

In vitro activities of trovafloxacin and three other fluoroquinolones against 12 fluoroquinolone-resistant mutants of M. hominis and one fluoroquinolone-resistant mutant of U. urealyticum

Organism	Amino acid change in QRDR ofa:			MIC (μg/ml)b
	GyrA	ParC	ParE	TVA	SPX	OFX	CIP
M. hominis
PG21	None	None	None	0.03	0.06	1	1
Clinical isolatesc
MHa	Glu-87→Lys	Glu-84→Gly	None	0.5	2	8	16
MHb1	Ser-83→Leu	Ser-81→Pro	None	0.5	4	16	16
MHb2	Ser-83→Leu	Ser-81→Pro	None	0.5	4	16	16
MHc1	Ser-83→Leu	None	Asp-420→Asn	0.5	2	32	32
MHc2	Ser-83→Leu	None	Asp-420→Asn	0.5	2	32	32
In vitro mutantsd
IS1	Ser-83→Leu	None	None	0.12	0.5	2	4
P4	None	Ser-80→Ile	None	0.12	0.12	16	16
C1	None	None	Asp-420→Asn	0.12	0.12	16	16
N7	Ser-83→Leu	None	Asp-420→Asn	1	2	32	32
IIS1	Ser-83→Leu	Glu-84→Lys	None	2	16	32	32
IIS3A	Ser-83→Leu, Ser-84→Trp	None	None	4	16	64	32
IIIS3A1	Ser-83→Leu, Ser-84→Trp	Glu-84→Lys	None	8	32	>64	>64
U. urealyticum
Reference strain	None	None	None	0.12	0.25	1	2
Clinical isolate
UUa	Gln-83→Arg, Asp-95→Glu	Thr-122→Ala, Thr-133→Ala	None	4	32	64	>128

^aM. hominis and U. urealyticum GyrA, ParC, and ParE residues are numbered according to the coordinates for Escherichia coli GyrA, ParC, and ParE. 

^bTVA, trovafloxacin; SPX, sparfloxacin, CIP; ciprofloxacin, OFX; ofloxacin. 

^cFrom reference 5; the QRDRs of gyrA, gyrB, parC, and parE were sequenced for all clinical isolates. 

^dFrom references 2 and 4; the QRDRs of gyrA, gyrB, parC, and parE were sequenced for all in vitro strains.